Achillion
Pharmaceuticals Inc. (Nasdaq: ACHN) reported positive interim results from
two studies supporting a short duration, potentially best-in-disease
regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and
ACH-3422. Shares of the biopharmaceutical climbed $1.93 to $16.14.
Achillion reports positive interim results
December 22, 2014 at 12:58 PM EST